Dr. Simon John

Dr. John is the Robert L. Burch III Professor of Ophthalmic Sciences at Columbia University’s Vagelos College of Physicians and Surgeons.  Dr. John earned his Ph.D. in Biology and Human Genetics at McGill University in 1992. He trained under the eminent human geneticists Rizma Rozen and Charles Scriver, as well as Nobel Laureate Oliver Smithies. He has accumulated a wealth of experience in molecular biology, physiology, population genetics, animal models of complex diseases, and ocular diseases with a focus on glaucoma.  As a Professor and Principal Investigator at The Jackson Laboratory, Dr. John pioneered the use of mice for glaucoma research by adapting tools from the human clinic, as well as developing new tools and mouse models.


B.Sc., 1985, Joint Honors Zoology and Genetics, University College Cardiff, South Wales, UK 

Thesis: Chromosome Studies of the Brown Planthopper Nilaparvata lugens (Stål) 

Supervisor: Dr. Jerome Den Hollander 

Ph.D., 1992, Biology, McGill University, Biology Department, Montreal, Canada 

Thesis: Haplotypes and Mutations at the Phenylalanine Hydroxylase Locus in French Canadians 

Supervisors: Dr. Charles R. Scriver and Dr. Rima Rozen 


1995 - Present       Professor, The Jackson Laboratory, Bar Harbor, ME 

  (Assistant 1995-2001, Associate 2001-2006, Full 2006-2019, Adjunct 2019-present)

1997 - 2019             Research Assistant Professor (Ophthalmology) and then Graduate Professor, 

  Tufts University School of Medicine, Boston, MA

1998 - 2021             Investigator,  Howard Hughes Medical Institute

2000 - 2019             Graduate Faculty/Cooperating Professor, Genomics, University of Maine, Orono, ME

2019 - Present       Adjunct Professor, Genetics Program, Tufts University Graduate School

2019 - Present Affiliate of the Jackson Laboratory

2019 - Present       Affiliate of the New York Genome Center

2019 - Present       Robert L. Burch III Professor of Ophthalmic Sciences and Member of the Zuckerman Institute, Columbia University, New York, NY


AWARDS (selected)                                                                                                                        

1997 & 1998                   Ruth Salta Junior Investigator Achievement Award, American Health Assistance Foundation

2004                                         Cogan Award, Association for Research in Vision & Ophthalmology

2004, 2013 & 2015       Lewis  Rudin Glaucoma Prize

2006                                         Global Glaucoma Award, Association of International Glaucoma Societies 

2008                                        Alcon Research Institute Award

2013                                        Bressler Vision Science Award

2020                                        The Sanford and Susan Greenberg Visionary Prize to End Blindness by 20/20


Simon John attributes his early interest in science to a library book about rainbows, an uncle who taught him to use a microscope, and the snakes he caught near his Welsh hometown. His passion for genetics was sparked by his father, who bred finches as a hobby.  Dr. John watched with amazement as his father mated the drabbest birds to produce offspring with stunning cinnamon plumage. “That got me interested in natural variation from a very early age,” he says.

Dr. John now studies the genetics of glaucoma, a potentially blinding eye disease that affects up to 70 million people worldwide. It results from damage to the optic nerve and is often preceded by high intraocular pressure. Partly because of his own poor eyesight, Dr. John empathizes with people who have more serious problems. “I want to understand the mechanism of glaucoma, with the goal of suggesting new ways to improve vision care,” he explains.

He became interested in this complex disease while studying the causes of high blood pressure, because he wondered if certain peptides might also control pressure inside the eye. Scouring the scientific literature, he was shocked to discover how little was known about glaucoma at the molecular level.

When he moved to the Jackson Laboratory in Maine in 1995, Dr. John decided to study glaucoma in an animal model. “I thought it would be easy to take the genes we had implicated in high blood pressure and work with them in the mouse eye,” he says.

But many scientists who studied glaucoma at that time had a low opinion of the mouse. “Some people told me I was wasting my time using mice for glaucoma research, because mice were anatomically inappropriate,” he says.

Through painstaking anatomical studies, Dr. John showed that the pertinent structures in the eyes of mice and men have a lot in common. Over their early years, he and his group developed the first mouse models of glaucoma, developed the necessary tools for studying them, and adapted human eye exams to mice. “Now all of the powerful tools of classical and modern mouse genetics can be used to study glaucoma,” he says. “I’m very proud of the way that has taken off.”

Using one of these mouse models, his group discovered that errors in a gene that codes for a type of collagen cause a glaucoma-like condition. Realizing that this collagen also strengthens blood vessels, they showed that the gene predisposes mice and humans to bleeding in the brain. “This work suggests possible behavioral and medical interventions that could massively reduce the risk of hemorrhagic complications and sudden death in families with this gene,” he says. “For example, individuals in those families could avoid playing contact sports or exercising too vigorously.”

Other mouse models have generated some surprising suggestions for preventing glaucoma. Dr. John studied a mouse with defects in a gene called Cyp1b1, which human geneticists had associated with a devastating glaucoma of infants and toddlers. By crossing those mice and strains with other genetic constitutions,  Dr. John discovered a gene that modulates the effects of Cyp1b1 defects on the eye. That gene codes for an enzyme that makes L-DOPA, a naturally occurring amino acid used to treat Parkinson’s disease. When his group spiked the drinking water of female mice with L-DOPA before and during pregnancy, the effects of the Cyp1b1 defects were largely prevented. “That’s very exciting, because there are many ways to adjust L-DOPA levels,” he says. If L-DOPA has the same effect in humans and passes the appropriate safety trials, it could be given to pregnant women who have a defective Cyp1b1 gene and whose children are at risk for glaucoma. Or such women might get enough L-DOPA simply by eating beans.

Another insight into glaucoma prevention was totally unexpected. Dr. John was studying mice that are prone to a type of glaucoma in which the iris falls apart and the eye’s drainage channels become damaged by pigment and debris. By the time the animals are middle-aged, their optic nerve is usually ruined because of the high pressure inside the eye.

To explore mechanisms contributing to this condition, Dr. John’s group gave the mice one high dose of radiation before transplanting them with bone marrow. As the animals aged, most of them had healthy optic nerves, even though they still had iris disease and high intraocular pressure. “We could hardly believe it. That was the biggest surprise of my career,” says Dr. John, who then contacted scientists who are following the lives of more than 10,000 survivors of the Hiroshima and Nagasaki atomic bombs. It turned out that the survivors who received the highest dose of radiation from the atomic bombs were the least likely to have glaucoma.

In collaboration with physicists and engineers, Dr. John devised ways to target specific amounts of radiation to parts of the tiny mouse eye to determine the molecular mechanism of protection. They discovered that radiation of the optic nerve itself prevents glaucoma. This raises the possibility that it might one day be possible for ophthalmologists to give patients a dose of radiation that would be as safe as a dental x-ray and that would protect against glaucoma for life. “That’s a pipe dream right now,” he says. “But it will be fantastic if it works.”

More recently, his group discovered that metabolism is perturbed in glaucoma with disturbances to mitochondrial function and structure preceding the development of glaucoma in mice. Further, they demonstrated that declining NAD levels, with aging, render retinal cells susceptible to succumbing to high pressure inside the eye (IOP, a key factor in glaucoma) and glaucomatous demise.  They continued to show that dietary supplementation with a form of vitamin B3 (a NAD precursor known as nicotinamide) protects retinal cell health and is profoundly protective from glaucoma in mice. 

In 2019, Dr. John and his lab joined the Department of Ophthalmology at Columbia University, where they continue to work on the role of metabolism in glaucoma. They have a strong interest in nutritional and lifestyle influences on ocular disease. Major goals are to develop preventative strategies that extend the healthspan (wellness) of the eye. They are developing nutritional supplementation strategies that support metabolism and cellular bioenergetics. In addition to nicotinamide, Dr. John's research discovered altered metabolism of both glucose and pyruvate in glaucoma and that combined treatment with both pyruvate and nicotinamide is more effective than treating with nicotinamide alone.

Dr. John has served on various advisory panels to the National Institute of Health and other agencies. He is a member of various professional organizations including the American Association for the Advancement of Science and the Society for Neuroscience. He has received various awards for his research. Dr. John was honored in both 1997 and 1998 with the Ruth Salta Junior Investigator Achievement Award from the National Glaucoma Research Program of the American Health Assistance Foundation. He received the Cogan Award in 2004 from the Association for Research in Vision and Ophthalmology to recognize his important contributions to ophthalmology and visual science. His work also received the  Lewis Rudin Glaucoma Prize from the New York Academy of Medicine for outstanding work in glaucoma in 2004, 2013, and 2015. In 2006, he received the Global Glaucoma Award from the Association of International Glaucoma Societies for daring, breakthrough, creative, original body of work and for most important glaucoma paper in 2005. Most recently, he was honored with the Sanford and Susan Greenberg Visionary Prize to End Blindness by 20/20, an award that honored members in the medical and scientific communities who have led exemplary and undeniable advances in the fight to end blindness.   

Support Our Research  

Your donation supports important new advances